Adua, Sally J.
Arnal-Estapé, Anna http://orcid.org/0000-0003-0490-7040
Zhao, Minghui http://orcid.org/0000-0001-8928-9258
Qi, Bowen
Liu, Zongzhi Z.
Kravitz, Carolyn http://orcid.org/0000-0003-0357-8986
Hulme, Heather
Strittmatter, Nicole http://orcid.org/0000-0003-1277-9608
López-Giráldez, Francesc http://orcid.org/0000-0001-7476-9822
Chande, Sampada http://orcid.org/0000-0001-7975-9332
Albert, Alexandra E.
Melnick, Mary-Ann
Hu, Bomiao
Politi, Katerina
Chiang, Veronica
Colclough, Nicola
Goodwin, Richard J. A. http://orcid.org/0000-0001-5699-8488
Cross, Darren http://orcid.org/0000-0002-5227-2871
Smith, Paul http://orcid.org/0000-0002-2812-5978
Nguyen, Don X. http://orcid.org/0000-0003-0324-5604
Funding for this research was provided by:
George Pfeiffer fellowship
AstraZeneca (N/A)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA166376, R01CA191489, P50CA196530, U01CA235747)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 18 August 2021
Accepted: 10 November 2022
First Online: 12 December 2022
Competing interests
: D.X.N. received research funding from AstraZeneca Inc. V.C. received consulting fees from Monteris Medical Inc and Clearpoint Medical Inc. K.P. is co-inventor on a patent licensed to Molecular MD for EGFR T790M mutation testing (through MSKCC). K.P. has received Honoraria/Consulting fees from Janssen, Takeda, NCCN, Novartis, Merck, AstraZeneca, Tocagen, Maverick Therapeutics, Dynamo Therapeutics, Halda and research support from AstraZeneca, Kolltan, Boehringer Ingelheim, Roche, D2G Oncology and Symphogen. H.H., N.S., M.A.M., N.C., R.J.A.G., D.C., P.S. are AstraZeneca employees and own company stocks and shares. The remaining authors declare no competing interests.